期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

儿童狼疮性肾炎治疗细节——达标治疗重要性与控制尿蛋白 被引量：2

Details of the treatment for lupus nephritis in children——importance of reach-the-standard treatment and control of urinary protein
原文传递
导出
摘要 系统性红斑狼疮（systemic lupus erytcthematosus，SLE）有肾损伤表现，即狼疮性肾炎（lupus nephritis，LN），不仅是儿童SLE最常见和最严重危及生命的主要原因之一，也是影响远期生命质量的关键。儿童LN比成人多见且严重，发病率高达70％～80％，90％在发病第1年内出现。临床可表现为孤立性血尿和（或）蛋白尿型、
作者 蒋小云
机构地区 中山大学附属第一医院儿科
出处 《中国实用儿科杂志》 CSCD 北大核心 2012年第10期724-728,共5页 Chinese Journal of Practical Pediatrics
关键词 系统性红斑狼疮 狼疮性肾炎 儿童 systemic lupus erythematosus lupus ne phritis child
分类号 R72 [医药卫生—儿科]
  • 相关文献

参考文献24

  • 1Bertsias GK, Tektonidou M, Amoura Z, et al.Joint European League Against Rheumatism and European Renal Associa- tion-European Dialysis and Transplant Association (EULAR/ ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis [J].Ann Rheum Dis, 2012 [in the press ].
  • 2Eknoyan G, Lameire N.DKIGO clinical practice guideline for glo- merulonephritis lupus nephritis[J].Kidney Int, 2012, 2 (2) : 221-232.
  • 3Gorriz JL, Martinez-Castelao A.Proteinuria: detection and role in native renal disease progression [J].Transplantation Rev, 2012, 26(1):3-13.
  • 4Hahn BH, Mcmahon MA, Wilkinson A, et al.American College of Rheumatology Guidelines for screening, treatment, and man- agement of lupus nephritis[J].Arthritis Care Res, 2012,64(6) : 797-808.
  • 5Siso A, Ramos-Casats M, Bov6 A, et al.Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival[J].Lupus,2008,17(4): 281-288.
  • 6Pons-Estel GJ, Alarc6n GS, McGwin Jr G, et al.Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort [J].Arthritis Rheum, 2009,61 (6) : 830-839.
  • 7Kaiser R, Cleveland CM, Criswell LA.Risk and protective fac- tors for thrombosis in systemic lupus erythematosus : results from a large, multiethnic cohort [J].Ann Rheum Dis, 2009,68 (2) : 238-241.
  • 8Kunz R, Friedrich C, Wolbers M, et al.Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the re- nin angiotensin system on proteinuria in renal disease [J].Ann Intern Med ,2008,148( 1 ) :30-48.
  • 9儿童常见肾脏疾病诊治循证指南（试行）（六）：狼疮性肾炎诊断治疗指南[J].中华儿科杂志,2010,48(9):687-690. 被引量：39
  • 10Weiss JE.Pediatric systemic lupus erythematosus: more than a positive antinuclear antibody [J].Pediatr Rev, 2012, 33 (2) : 62-74.

二级参考文献37

  • 1刘志红,黎磊石.狼疮肾炎的治疗[J].中国实用内科杂志：临床前沿版,2006,26(1):86-87. 被引量：13
  • 2王禹,刘晓丹,栗霄立,王力宁,周希静.亚临床狼疮肾炎的临床病理分析及随访[J].中华肾脏病杂志,2006,22(6):370-371. 被引量：4
  • 3Austin HA,Muenz LR,Joyce KM,et al.Prognosic factors in lupus nephritis.Contribution of renal histologic data.Am J Med,1983,75:382-391.
  • 4Esdaile JM JL,MacKenzie T,Kashgarian M,et al.The benefit of early treatment with immunosuppressive agents in lupus nephritis.J Rheumatol,1994,21:2046-2051.
  • 5Houssiau FA VC,D'Cruz D,Sebastiani GD,et al.Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis:lessons from long-term followup of patients in the EuroLupus Nephritis Trial.Arthritis Rheum,2004,50:3934-3940.
  • 6Sauter M,Anders HJ.Lupus nephritis.Minerva Med,2007,98:749-758.
  • 7Flanc RS,Roberts MA,Strippoli GF,et al.Treatment of diffuse proliferative lupus nephritis:a meta-analysis of randomized controlled trials.Am J Kidney Dis,2004,43:197-208.
  • 8Grootscholten CLG,Hagen EC,van den Wall Bake AW,et al.Dutch working party on systemic lupus erythematosus.Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis.A randomized controlled trial.Kidney Iht,2006,70:732-742.
  • 9Bertsias G,Ioannidis JP,Boletis J,et al.EULAR recommendations for the management of systemic lupus erythematosus.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics.Ann Rheum Dis,2008,67:195-205.
  • 10Chan TM,Tse KC,Tang CS,et al.Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.J Am Soc Nephrol,2005,16:1076-1084.

共引文献508

同被引文献30

  • 1徐珍娥,李秋.不同性别系统性红斑狼疮患儿的临床特点[J].实用儿科临床杂志,2009,24(9):656-658. 被引量：8
  • 2Michael W, Matthew J, David J, et al. Mycophenolate mofetil for in- duction therapy of lupusnephritis : a systematic review and meta anal- ysis [ J ]. Clin J Am Soc Nephro,2007, ( 2 ) :968 - 975.
  • 3Kamanamool N, McEvoy M, Attia J, et al. Efficacy and Adverse E- vents of Mycophenolate Mofetil Versus Cyclophosphamide for Induc- tion Therapy of Lupus Nephritis : Systematic Review and Meta-Analy- sis[J]. Medicine,2010,89(4) :227 -235.
  • 4Grootscholten C, Bajema IM, Florquin S, et al. Treatment with cyclo- phosphamide delays the progression of chronic lesions more effective- ly than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis[ J ]. Arthritis and Rheuma- tism,2007,56 ( 3 ) :924 - 937.
  • 5Zhang FS,Nie YK,Jin XM, et al. The efficacy and safety of lefluno- mide therapy in lupus nephritis by repeat kidney biopsy [ J ]. Rheu- matolInt, 2009,29 ( 11 ) : 1331 - 1335.
  • 6Miyasaka N, Kawai S, Hashimoto H, et al. Efficacy and safety of ta- crolimus for lupus nephritis:a placebo-controlled double-blind multi- center study [ J ]. Modern rheumatology ,2009,19 (6) :606 - 615.
  • 7Chen W,Tang X, Liu Q, Chen W, et al. Short-term outcomes of in- duction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis : A muhicenter randomized clinical trial [ J ]. Am J Kidney Dis ,2011,57 (2) :235 - 244.
  • 8Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analy- sis of the use of B cell depletion therapy in systemic lupus erythema- tosus at University College London Hospital: the first fifty patients [ J]. Arthritis Rheum,2009,61 (4) :482 - 487.
  • 9Elie C, Brocheriou I, Knebelmann B, et al. Rituximab in Severe Lu- pus Nephritis:Early B-Cell Depletion Affects Long-Term Renal Out- come [ J ]. CJASN .2009.4 ( 3 ) : 579 - 587.
  • 10Illei GG, Shirota Y, Yarboro CH,et al. Tocilizumab in systemic lupus erythematosus : data on safety, preliminary efficacy, and impact on cir- culating plasma cells from an open-label phase 1 dosage-escalation study[ J ]. Arthritis and Rheumatism ,2010,62 ( 2 ) :542 - 552.

引证文献2

中国实用儿科杂志
2012年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部